AbbVie (ABBV) Given Daily News Sentiment Score of 0.17
Headlines about AbbVie (NYSE:ABBV) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AbbVie earned a news impact score of 0.17 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5724300587445 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Hot Tickers: AbbVie Inc. (ABBV), GameStop Corp. (GME) – Market Movers (financialqz.com)
- AbbVie Inc.: AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call – The Wall Street Transcript (twst.com)
- Your Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com – Seeking Alpha (seekingalpha.com)
- AbbVie Target of Unusually Large Options Trading (ABBV) (americanbankingnews.com)
- AbbVie Inc (ABBV) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
Shares of AbbVie (NYSE ABBV) traded up $1.07 during mid-day trading on Friday, hitting $100.34. 4,370,000 shares of the stock were exchanged, compared to its average volume of 4,470,000. AbbVie has a 52 week low of $59.27 and a 52 week high of $101.28. The firm has a market cap of $159,950.00, a PE ratio of 24.35, a price-to-earnings-growth ratio of 1.19 and a beta of 1.53. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The company had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 23.32% and a return on equity of 102.55%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.21 EPS. research analysts forecast that AbbVie will post 5.54 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.83%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is 68.93%.
Several equities analysts recently commented on the stock. Vetr cut shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $113.08 target price for the company. in a research note on Monday, January 8th. Barclays reiterated a “hold” rating and set a $68.00 target price on shares of AbbVie in a research note on Thursday, September 28th. BMO Capital Markets set a $84.00 price objective on shares of AbbVie and gave the company a “hold” rating in a research note on Thursday. Evercore ISI restated an “outperform” rating and issued a $100.00 price objective (up previously from $95.00) on shares of AbbVie in a research note on Saturday, September 30th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of AbbVie in a research note on Tuesday, January 2nd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $100.94.
In related news, SVP Timothy J. Richmond sold 87,040 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the sale, the senior vice president now owns 113,118 shares in the company, valued at approximately $11,136,467.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the sale, the insider now owns 81,287 shares of the company’s stock, valued at approximately $7,360,537.85. The disclosure for this sale can be found here. Insiders have sold a total of 494,676 shares of company stock valued at $47,237,938 in the last quarter. 0.23% of the stock is currently owned by corporate insiders.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.